J Gynecol Oncol.  2024 Jul;35(4):e37. 10.3802/jgo.2024.35.e37.

Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial

Affiliations
  • 1Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan
  • 2Department of Biostatistics, School of Medicine, Yokohama City University, Kanagawa, Japan
  • 3Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan
  • 4Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan
  • 5Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
  • 6Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine, Gunma, Japan
  • 7Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  • 8Department of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
  • 9Department of Obstetrics and Gynecology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan
  • 10Department of Gynecology, Gunma Prefectural Cancer Center, Gunma, Japan
  • 11Department of Gynecologic Oncology, Hyogo Cancer Center, Hyogo, Japan
  • 12Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
  • 13Department of Obstetrics and Gynecology, Shin-Yurigaoka General Hospital, Kanagawa, Japan

Abstract


Objective
In Japan, perioperative prophylaxis of pulmonary embolism (PE) in gynecologic cancer patients with preoperative asymptomatic venous thromboembolism (VTE) has not been well established yet. The GOTIC-VTE trial was a prospective, multi-center, single-arm clinical trial to investigate the prevention of postoperative symptomatic PE onset by seamless anticoagulant therapy from the preoperative period to 4 weeks after surgery instead of using intermittent pneumatic compression.
Methods
Anticoagulant therapy was started immediately after asymptomatic VTE diagnosis and stopped preoperatively according to the rules of each institution. Unfractionated heparin administration was resumed within 12 hours postoperatively, and this was followed by the switch to low-molecular-weight heparin and subsequently, edoxaban; this cycle was continued for 28 days. Primary outcome was the occurrence of symptomatic PE in 28 days postoperatively. Secondary outcomes were the incidence of VTE-related events in 28 days and 6 months postoperatively and protocol-related adverse events.
Results
Between February 2018 and September 2020, 99 patients were enrolled; of these, 82patients were assessed as the full analysis set, including 58 for ovarian cancer, fallopian tube, or peritoneal cancer; 21 for endometrial cancer; and 3 for cervical cancer. No symptomatic PE was observed within 28 days postoperatively; two patients had bleeding events (major bleeding and clinically relevant nonmajor bleeding) and three had grade 3 adverse events (increased alanine transaminase, aspartate aminotransferase, or gamma-glutamyl transferase).
Conclusion
The multifaceted perioperative management for gynecologic malignancies with asymptomatic VTE effectively prevented postoperative symptomatic PE. Trial Registration: JRCT Identifier: jRCTs031180124

Keyword

Anticoagulants; Gynecologic Neoplasms; Gynecologic Surgery; Pulmonary Embolism; Venous Thromboembolism
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr